CN100528164C - 用于增强认知保养的抑制素产品 - Google Patents

用于增强认知保养的抑制素产品 Download PDF

Info

Publication number
CN100528164C
CN100528164C CNB038073854A CN03807385A CN100528164C CN 100528164 C CN100528164 C CN 100528164C CN B038073854 A CNB038073854 A CN B038073854A CN 03807385 A CN03807385 A CN 03807385A CN 100528164 C CN100528164 C CN 100528164C
Authority
CN
China
Prior art keywords
statin
inhibin
galantamine
galanthamine
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038073854A
Other languages
English (en)
Chinese (zh)
Other versions
CN1642555A (zh
Inventor
S·利利恩费尔德
E·M·古特曼
R·J·格拉斯普尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN1642555A publication Critical patent/CN1642555A/zh
Application granted granted Critical
Publication of CN100528164C publication Critical patent/CN100528164C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
CNB038073854A 2002-04-02 2003-03-28 用于增强认知保养的抑制素产品 Expired - Fee Related CN100528164C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36928502P 2002-04-02 2002-04-02
US60/369,285 2002-04-02

Publications (2)

Publication Number Publication Date
CN1642555A CN1642555A (zh) 2005-07-20
CN100528164C true CN100528164C (zh) 2009-08-19

Family

ID=28675573

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038073854A Expired - Fee Related CN100528164C (zh) 2002-04-02 2003-03-28 用于增强认知保养的抑制素产品

Country Status (21)

Country Link
EP (1) EP1492539B1 (https=)
JP (1) JP2005525391A (https=)
KR (1) KR100986194B1 (https=)
CN (1) CN100528164C (https=)
AT (1) ATE331523T1 (https=)
AU (1) AU2003226753B2 (https=)
BR (1) BR0308293A (https=)
CA (1) CA2480275C (https=)
CY (1) CY1105545T1 (https=)
DE (1) DE60306503T2 (https=)
DK (1) DK1492539T3 (https=)
EA (1) EA013069B1 (https=)
ES (1) ES2268393T3 (https=)
IL (2) IL164317A0 (https=)
MX (1) MXPA04009535A (https=)
NO (1) NO20044698L (https=)
NZ (1) NZ536111A (https=)
PL (1) PL211160B1 (https=)
PT (1) PT1492539E (https=)
UA (1) UA79605C2 (https=)
WO (1) WO2003082298A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
MXPA06011969A (es) * 2004-04-14 2006-12-15 Warner Lambert Co Combinacion terapeutica para tratamiento de la enfermedad de alzheimer.
WO2005123068A2 (en) * 2004-06-08 2005-12-29 Axonyx, Inc. Methods of dealying alzheimer’s disease progression using a beta-amyloid precursor protein inhibitor and a hmg coa reductase inhibitor
GB0607946D0 (en) * 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
AU2007299726A1 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
TWI432195B (zh) 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
WO2015089349A1 (en) * 2013-12-13 2015-06-18 Tabaczynski David A Inhibition of isoprenoid biosynthetic pathways to treat neuroinflammatory disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1222077A (zh) * 1996-06-14 1999-07-07 詹森药业有限公司 快速溶出的雪花胺氢溴酸盐片剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1222077A (zh) * 1996-06-14 1999-07-07 詹森药业有限公司 快速溶出的雪花胺氢溴酸盐片剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Statins and the risk of dementia. H. JICK ET AL.The LANCET,Vol.356 No.9242. 2000 *

Also Published As

Publication number Publication date
NO20044698L (no) 2004-10-29
IL164317A (en) 2010-04-29
EA013069B1 (ru) 2010-02-26
PL371551A1 (en) 2005-06-27
EP1492539A1 (en) 2005-01-05
AU2003226753A1 (en) 2003-10-13
AU2003226753B2 (en) 2007-06-28
IL164317A0 (en) 2005-12-18
JP2005525391A (ja) 2005-08-25
CA2480275A1 (en) 2003-10-09
EA200401295A1 (ru) 2005-02-24
WO2003082298A1 (en) 2003-10-09
CA2480275C (en) 2011-08-16
NZ536111A (en) 2006-03-31
EP1492539B1 (en) 2006-06-28
CN1642555A (zh) 2005-07-20
KR100986194B1 (ko) 2010-10-07
DE60306503D1 (de) 2006-08-10
CY1105545T1 (el) 2010-07-28
BR0308293A (pt) 2004-12-28
UA79605C2 (en) 2007-07-10
KR20040096608A (ko) 2004-11-16
PL211160B1 (pl) 2012-04-30
PT1492539E (pt) 2006-11-30
DE60306503T2 (de) 2007-06-21
DK1492539T3 (da) 2006-10-30
ES2268393T3 (es) 2007-03-16
ATE331523T1 (de) 2006-07-15
MXPA04009535A (es) 2005-01-25
HK1079688A1 (zh) 2006-04-13

Similar Documents

Publication Publication Date Title
Lechin et al. Pimozide therapy for trigeminal neuralgia
Ritsner et al. L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study
EP2991637B1 (en) Fenfluramine for use in the treatment of dravet syndrome
VAN DER VELDE Effectiveness of lithium carbonate in the treatment of manic-depressive illness
US20170042878A1 (en) Compositions comprising scopolamine and ketamine in the treatment of depression
EP2004191A1 (en) Trimetazidine for use in the treatment of fibromyalgia syndrome and related conditions
CN100528164C (zh) 用于增强认知保养的抑制素产品
WO2007116074A1 (en) Trimetazidine for use in the treatment of fibromyalgia syndrome and related conditions
RU2268725C2 (ru) Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных расстройств
Courtney et al. Suzetrigine: A novel selective sodium channel inhibitor for pain
CN109069466A (zh) 5-ht6受体拮抗剂用于治疗阿尔茨海默病伴情感淡漠共病
RU2535019C1 (ru) Седативное и спазмолитическое средство
CN107737136A (zh) 一种药物组合物在预防和/或治疗高脂血症与降血糖中的用途
Grama et al. Effect of caffeine on pain management
CN101028265A (zh) 一种改善睡眠调整睡醒节律的黑白药物组合物
EP0440851A1 (en) Use of buspirone for the treatment of depressions
HK1079688B (en) Statin product for enhancing cognitive maintenance
Talreja et al. Healing and Hallucinations: A Comprehensive Look at Datura
HK40112834A (zh) 用於痴呆和神经变性病况中的激越、精神病和认知衰退的环苯扎林治疗
WO2023036820A1 (en) Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
JPH03246225A (ja) メランコリーうつ病の治療法
HK1256346A1 (en) Fenfluramine for use in the treatment of dravet syndrome
HK1256346B (en) Fenfluramine for use in the treatment of dravet syndrome
Elliott et al. Galantamine HBr Tablets (Reminyl—Janssen Pharmaceutica)
Hardesty Drug Therapy for Dementia—Affecting More Than Just the Mind

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1079688

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1079688

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090819

Termination date: 20210328

CF01 Termination of patent right due to non-payment of annual fee